Reports Q1 revenue $73.46M, consensus $71.26M. Ming Hsieh, chairperson of the board of directors and CEO, said, “I am pleased with the first quarter results and momentum we are seeing so far in 2025. Our Laboratory Services business is well-positioned for growth, and we continue to progress our Therapeutic Development pipeline.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: